Brexit bonus? Johnson shares international credit for vaccine approval
Reuters
Published Dec 02, 2020 18:19
LONDON (Reuters) - British Prime Minister Boris Johnson on Wednesday said that the country's approval of Pfizer/BioNTech's COVID-19 vaccine candidate was a result of international efforts, declining to credit Brexit for the fast pace of the regulatory process.
German Health Minister Jens Spahn had earlier said that it was misplaced to celebrate the approval of the vaccine as some sort of victory for Brexit Britain. The European Medical Agency (EMA) is still assessing the shot, while Britain has approved the vaccine for emergency use, a move allowed under European law which will regulate the sector until the end of the year.
Asked if the accelerated approval was Britain's first "big Brexit bonus", Johnson gave credit to the UK's Vaccine Taskforce but also said that all seven vaccines that Britain has ordered were the result of global efforts.
"You've got scientists around the world coming together to make this possible. And it's a truly it's a truly international thing and very, very moving to see it," Johnson said at a news conference.
Pressed to give a clearer answer, Johnson said he was exercising a "self-denying ordinance" of diplomacy and tact.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.